As part of the leading pack of companies in the psychedelic healthcare space, Silo Pharma exclusively funds and licenses innovative psychedelic research and treatments that are pushing the industry forward.
By most estimates, the psychedelic healthcare market is expected to reach $10 Billion by 2027.
By bringing innovative new solutions with psychedelics, Silo Pharma is dedicated to revolutionizing the psychedelic healthcare industry and improving the lives of patients suffering from various disorders.
New Solutions are Needed to
Solve Old Problems
Treatment for mental, emotional, and neurological disorders have remained stagnant for decades.
And the psychedelic substances that could provide the innovative relief needed for patients remain illegal in most cases.
Despite their current status,
research and experiments with
psychedelic substances go as far
back as the beginning of human history.
Ancient religious cults drank psychedelic brews to commune with deities. Roman rulers and politicians were required to undergo psychedelic treatment prior to serving in the highest ranks. And by the 1950s, mainstream researchers were studying the beneficial effects of drugs such as LSD, psilocybin, and MDMA.
But promising results were cut short when governments deemed these natural substances to be as dangerous and addictive as heroin and crack cocaine.
Positive Change Comes as
New Markets Emerge
Silo Pharma has seen the immense potential of the psychedelic research market and has set its sights on commercializing life-saving treatments using the benefits of psychedelics.
With recent advancements in scientific understanding and popular movements to legalize cannabis, psychedelic substances seem close to getting the legal attention (and deregulation) they deserve. Within the last few years the state of Oregon and the city of Denver have decriminalized psilocybin mushrooms. Other states are looking to do the same.
Understanding that the Psychedelic market is predicted to boom as the government deregulates access to psychedelics, Silo Pharma has already engaged in a number of exclusive projects using substances such as psilocybin, MDMA, and ketamine.
Silo Pharma’s Foresight and
Dedication are Paying Off
Silo Pharma received a $1 Million up-front licensing deal for a novel therapeutic cancer treatment.
Studies have shown that compounds found in psilocybin-containing ‘magic’ mushrooms have serious anti-inflammatory effects.
Using a novel peptide drug delivery system that targets inflammation in the brain and spinal cord, Silo Pharma is developing a new way to administer these compounds to cancer patients.
This new and exciting drug delivery system uses ‘homing-peptides’ to target and reduce inflammation, potentially sidestepping the hallucinogenic effects of magic mushrooms in the process.
Silo Pharma licensed a novel ‘Peptide-Guided Drug Delivery’ treatment for multiple sclerosis.
Harvard research has shown the immense benefits of peptide treatment for Multiple Sclerosis.
Silo Pharma understands the impact of these new treatments and entered into an exclusive option agreement with the University of Maryland Baltimore to develop an innovative central nervous system-homing peptide treatment to slow down the destructive effects of MS.
Research is also being conducted to identify similar diseases that could be treated with the same tech.
According to a market assessment by InsightAce, the peptide pharmaceutical market is estimated to reach $4.32 Billion by 2030.
Silo Pharma and Zylo Therapeutics, Inc. (ZTI) teamed up to develop new ways to administer therapeutic ketamine treatments.
Ketamine remains one of the only legal psychedelic substances.
In addition to its anesthetic effects, ketamine has been shown to massively improve the mental and emotional states of patients suffering from depression and anxiety.
Using ZTI’s patented Z-Pod technology, Silo Pharma is building out a new way to safely deliver time-released and dosage-controlled ketamine in a wearable patch, similar to nicotine patches.
Silo Pharma partnered exclusively with the University of Maastricht to study the effects of ‘microdosing’.
Microdosing is best described as taking small amounts of a psychedelic substance over a period of time.
Silo Pharma partnered with the University of Maastricht to study the effects of LSD and psilocybin microdosing in Parkinson’s patients to improve patient well-being.
CEO and Founder of Silo Pharma, Eric Weisblum, comments, “Now more than ever, creative new therapies are needed to address the growing mental health challenges. Early lab studies with psychedelic drugs have shown promising indications producing neurological responses that could potentially treat a wide variety of emotional and neurological disorders.”
Silo Pharma was founded in January 2020 by 25-year Wall Street veteran Eric Weisblum.
After playing a key role in successful biotech companies such as Aikido Pharma, Mr. Weisblum set his sights on starting his own biotech company to transform tomorrow’s healthcare by capitalizing on the emerging psychedelic market.
“As one of the first US publicly-traded entrants into the emerging psilocybin-based drug market,” Mr. Eisblum said, “we are pursuing opportunities to sponsor clinical research and subsequently license drug therapies for the treatment of major emotional disturbances such as PTSD, depression, anxiety and addiction as well as other neurological disorders such as Alzheimer’s and Parkinson’s.”
Since its founding, Silo Pharma has entered several exclusive licensing deals with top psychedelic researchers to develop innovative solutions for various disorders such as PTSD, Alzheimer’s, Parkinsons, and Cancer.
A Tight-Knit Board of Directors
Focusing on alignment as much as experience, Silo Pharma’s board represents decades of experience in finance, psychiatry, and biomedical science.
Mr. Weisblum has experience in both in-licensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments.
He is a medical doctor and researcher with a background in biomedical science. Having worked on all sides of healthcare including research, operations, and patient care, Dr. Muñoz is well-suited for the Board at Silo Pharma.
He has been in business management for over 40 years. He possesses a wide and varied skill set including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting.
He is a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center and has extensive experience in neuroscience and psychedelic research. His laboratory is actively investigating psilocybin therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with Parkinson's Disease.
His background is in neurobiology, neuropsychopharmacology, and psychiatry and currently serves as chair and professor with the Department of Psychiatry and Behavioral Sciences at The University of Texas at Austin.
Silo Pharma is Helping Pave
the Way to a Psychedelic Future
By continuing to seek out and license novel, life-changing psychedelic treatments, Silo Pharma is quickly establishing itself as one of the forefront psychedelic research and treatment companies.
In line with this goal, Silo Pharma has entered into agreements with premier research organizations as recent as March 2022 and submitted its application for NASDAQ up-listing around the same time.
“After the exciting progress we have made over the last year,” says CEO Eric Weisblum, “up-listing to the NASDAQ is the next strategic step for Silo Pharma. A NASDAQ listing should provide greater liquidity for our investors, attract institutional investors, increase the visibility of the Company and raise our overall profile.”
In March 2022, Silo Pharma partnered with InvestorBrandNetowork to maximize its reach to wise and savvy investors.
Having seen the future of medical care before it becomes reality, Silo Pharma is uniquely positioned for major growth in the psychedelic research and treatment market.
Company Financials